AMArdhendu Kumar Maji

Ardhendu Kumar Maji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ardhendu Kumar Maji has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Artemisinin-Based Combination Therapy on Falciparum Malaria in Urban Kolkata: A Clinic-Based Report

    by Pabitra Saha, Swagata Ganguly, Soma Dutta, Pratip K. Kundu, Dilip K. Bera, Nandita Basu, Ardhendu K. Maji

    In India combination of artesunate + sulphadoxine-pyrimethamine has been implemented for uncomplicated falciparum malaria since 2010. We observed the impact of this intervention in urban Kolkata by analyzing data of Malaria Clinic from 2001 to 2013. In Kolkata P. vivax is perennial whereas P. falciparum infection is seasonal. Before ACT implementation P. falciparum percentage was as high as 50% which steadily decreased during four successive years post intervention. No change was observed in case of vivax cases. ACT is probably an effective measure in reducing falciparum malaria cases. Any artemisinin derivative combination should be explored in vivax malaria to reduce the overall malaria burden.


  • Comparative Efficacies of Artemisinin Combination Therapies in Plasmodium falciparum Malaria and Polymorphism of pfATPase6 , pfcrt , pfdhfr , and pfdhps Genes in Tea Gardens of Jalpaiguri District, India

    by Pabitra Saha, Subhasish K. Guha, Sonali Das, Shrabanee Mullick, Swagata Ganguly, Asit Biswas, Dilip K. Bera, Gaurangadeb Chattopadhyay, Madhusudan Das, Pratip K. Kundu, et al.

    In India, chloroquine has been replaced by a combination of artesunate and sulfadoxine-pyrimethamine (AS-SP) for uncomplicated P. falciparum malaria. Other available combinations, artemether-lumefantrine (AM-LF) and artesunate-mefloquine (AS-MQ), not included in the national program, are widely used by private practitioners. Little is known about the therapeutic efficacy of these artemisinin combinations and the prevalence of molecular markers associated with antimalarial drug resistance. A total of 157 patients with P. falciparum monoinfection were recruited and randomized into three study groups (AS-SP, AM-LF, and AS-MQ). All patients were followed up for 42 days to study the clinical and parasitological responses according to the WHO protocol (2009). We assessed the polymorphism of the pfATPase6 , pfcrt , pfdhfr , and pfdhps genes by the DNA-sequencing method. The PCR-corrected therapeutic efficacies of AS-SP, AM-LF, and AS-MQ were 90.6% (95% confidence interval [CI], 0.793 to 0.969), 95.9% (95% CI, 0.860 to 0.995), and 100% (95% CI, 0.927 to 1.00), respectively. No specific mutational pattern was observed in the pfATPase6 gene. All isolates had a K76T mutation in the pfcrt gene. In the pfdhfr-pfdhps genotype, quadruple mutation was frequent, and quintuple mutation was documented in 6.3% of P. falciparum isolates. The significant failure rate of AS-SP (9.5%), although within the limit (10%) for drug policy change, was due to SP failure because of prevailing mutations in pfdhfr , I 51 R 59 N 108 , with pfdhps , G 437 and/or E 540 . The efficacy of this ACT needs periodic monitoring. Artemether-lumefantrine and artesunate-mefloquine are effective alternatives to the artesunate-sulfadoxine-pyrimethamine combination.


  • Open Access

    Efficacy of oral miltefosine in visceral leishmaniasis in rural West Bengal, India

    by Ardhendu Kumar Maji, Pradyumna Patra, Subhasish K Guha, Pabitra Saha, Swagata Ganguly, Abhiram Chakraborty, Pratip K Kundu, Sachchidananda Sarker, Krishnangshu Ray

    Context: Visceral leishmaniasis (VL), also known as Kala-azar (KA) is a public health problem of tropical and subtropical countries, which infects about 12 million people annually, out of which about 1.5 million are new cases. India contributes a major share of the global burden of VL. For many years leishmaniasis has been treated with pentavalent antimonials. Antimony resistance is a problem in India and in other different geographic areas of the world. Amphotericin B deoxycholate and pentamidine isethionate are effective by parenteral administration and associated with toxicities. The quest for an effective, orally administered, non-toxic and less expensive alternative resulted in the identification of miltefosine (hexadecylphosphocholine). In India, therapeutic efficacy of miltefosine in VL was assessed by many groups of scientists, mainly from Bihar and Uttar Pradesh. No such data is available from West Bengal. Aims: The present study was designed to observe the efficacy of miltefosine in VL in rural West Bengal. Materials and Methods: A total of 71 parasitologically proven VL patients participated in the study who received miltefosine in accordance with the National Vector Born Disease Control Programme (NVBDCP) of India and were followed up for the following one year. Results: The overall efficacy of the drug was 93% and no significant adverse side effects were observed during the study period. Conclusions: The study concludes that miltefosine is effective, well tolerated, and easily administrable drug in the treatment of visceral leishmaniasis at the field levels.


  • Open Access

    DISTRIBUTION OF PFCRT HAPLOTYPES AND IN-VIVO EFFICACY OF CHLOROQUINE IN TREATMENT OF UNCOMPLICATED P. FALCIPARUM MALARIA BEFORE DEPLOYMENT OF ARTEMISININ COMBINATION THERAPIES IN URBAN POPULATION OF KOLKATA, INDIA

    by Pabitra Saha, Krishnangshu Ray, Pratip K. Kundu, Madhusudan DAS, Basudeb Mukherjee, Abhiram Chakravorty, Dilip K. Bera, Asit Biswas, Mitali Chatterjee, Swagata Ganguly, et al.

    A total of 101 P. falciparum positive patients were enrolled from urban population of Kolkata, India to determine the therapeutic efficacy of chloroquine as per 28 days follow-up schedule of WHO, 2003. All parasite strains were analyzed for P. falciparum chloroquine resistance transporter (pfcrt) haplotypes using DNA sequencing methodology. The PCR corrected chloroquine resistant P. falciparum was very high (76.3%, 95% CI 0.642-0.832) of which early treatment failure was (10%), and late treatment failure was (66.3%). K76T mutation was found in all parasite strains irrespective of therapeutic outcomes. Both the Venezuelan (SVMNT) and Southeast Asian (CVIET) haplotypes were prevalent in the study population with predominance of South East Asian haplotype (87.1%). The present study showed that incidence of CQ resistant P. falciparum malaria in Kolkata was very high and well above the WHO recommended cutoff level for change of drug policy. Recently introduced Artimisinine Combination Therapy by the Government of India to treat all P. falciparum cases is an appropriate step.


  • Open Access

    Efficacy of Chloroquine and Sulphadoxine‐Pyrimethamine either alone or in combination before introduction of ACT as first‐line therapy in uncomplicated Plasmodium falciparum malaria in Jalpaiguri District, West Bengal, India

    by Shrabanee Mullick, Sonali Das, Subhasish K. Guha, Dilip K. Bera, Samudra Sengupta, Debasis Roy, Pabitra Saha, Asit Biswas, Madhusudan Das, Krishnangshu Ray, et al.

    Objective In India, till recently, Chloroquine was used as first‐line therapy in areas with Chloroquine sensitive Plasmodium falciparum malaria cases. The National Vector Borne Disease Control Programme (NVBDCP) has introduced artemisinin combination therapy (ACT) as first‐line option to treat all P. falciparum cases in the country. This study was carried out to ascertain the efficacy of Chloroquine and Sulphadoxine‐Pyrimethamine, either alone or in combination, before the launch of ACT by NVBDCP. Methods A total of 300 P. falciparum malaria cases were enrolled randomly in three study arms, Chloroquine (CQ), Sulphadoxine‐Pyrimethamine (SP) and Chloroquine plus Sulphadoxine‐Pyrimethamine (CQ + SP). All patients were followed up for 28 days as per WHO (Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria, Geneva, 2003) Protocol. Paired blood samples of treatment failure cases were collected and subjected to MSP 1, MSP 2 and GLURP genotyping for differentiation between re‐infection and recrudescence. The data were analysed by Kaplan–Meier survival curve according to WHO standard procedures. Results The overall failure rate including both early treatment failure (ETF) and late treatment failure (LTF) of CQ, SP and CQ + SP were 61%, 14% and 8%, respectively, in the study area. Of 60 recurrent malaria cases, genotyping was successful in 49 cases, revealing that most of the (46/49; 94%) cases of recurrent malaria were due to recrudescence. Conclusion In Jalpaiguri District the overall failure rate of CQ was 61% and of SP 14%, which was well above the WHO recommended cut‐off threshold level (10%) for change of drug policy.